MorphoSys (NASDAQ:MOR) Rating Reiterated by Leerink Partnrs

MorphoSys (NASDAQ:MOR – Get Free Report)‘s stock had its “market perform” rating reissued by analysts at Leerink Partnrs in a research note issued to investors on Wednesday, PriceTargets.com reports. Leerink Partnrs also issued estimates for MorphoSys’ FY2026 earnings at ($0.78) EPS. A number of other equities research analysts have also weighed in on the stock. […]

Related Keywords

United States ,Leerink Partnrs ,Morgan Stanley ,Envestnet Asset Management Inc ,Qube Research Technologies Ltd ,Virtu Financial ,Goldman Sachs Group ,Morphosys Company Profile ,Jpmorgan Chase Co ,Get Free Report ,Technologies Ltd ,Envestnet Asset Management ,Morphosys Daily ,Morphosys ,Nasdaq Mor ,Humor ,Medical ,Reiterated Rating ,